Cohort study reveals higher recurrence risk in SM-EGN, indicating need for lifelong monitoring.
SM-EGN confers a persistently higher recurrence risk after curative ESD, consistent with the phenomenon of field cancerization. No significant difference in survival was observed in the limited second recurrence cohort, likely due to intensive monitoring and timely intervention. That hints to us that SM-EGN patients require lifelong, risk-adapted surveillance.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: